PERSEPHONELunsekimig for Adults with Eosinophilic Chronic Obstructive Pulmonary Disease
This study aims to evaluate the effectiveness of a treatment in reducing the annual rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations in adults with Eosinophilic COPD.
Lunsekimig
+ Placebo
Chronic Disease+5
+ Lung Diseases
+ Lung Diseases, Obstructive
Treatment Study
Summary
Study start date: September 16, 2025
Actual date on which the first participant was enrolled.This clinical trial aims to explore how effective and safe a drug called lunsekimig is for adults with a type of Chronic Obstructive Pulmonary Disease (COPD) that involves high levels of certain white blood cells, known as an eosinophilic phenotype. Some people with COPD continue to have symptoms that are hard to control despite standard treatments. This study hopes to find out if lunsekimig can help manage those symptoms better, potentially leading to improved treatment options for this group of patients. Participants in this study will receive injections under the skin of either lunsekimig or a placebo, which is a substance with no active drug, over a period of 48 weeks. The study will assess how well the drug works in controlling the symptoms of COPD and ensuring it is safe for use. While there are no specific details on the outcomes being measured, the focus will be on evaluating improvements in breathing and overall lung function.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.942 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 40 to 80 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.3 intervention groups are designated in this study
33.333% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 153 locations
Chandler Clinical Research Trials- Site Number : 8400025
Chandler, United StatesOpen Chandler Clinical Research Trials- Site Number : 8400025 in Google MapsPulmonary Associates - Phoenix - East Bell Road- Site Number : 8400114
Phoenix, United StatesEpic Medical Research - Surprise- Site Number : 8400096
Surprise, United StatesIMAX Clinical Trials- Site Number : 8400109
La Palma, United States